These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 23302410

  • 1. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.
    Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Reis RB.
    Int Braz J Urol; 2012; 38(6):717-27. PubMed ID: 23302410
    [Abstract] [Full Text] [Related]

  • 2. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G, Ferro M, Buonerba C.
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [Abstract] [Full Text] [Related]

  • 3. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
    Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.
    J Clin Oncol; 2006 Jul 01; 24(19):3089-94. PubMed ID: 16809734
    [Abstract] [Full Text] [Related]

  • 4. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX, Fong L, Small EJ.
    Expert Rev Vaccines; 2015 Jul 01; 14(12):1529-41. PubMed ID: 26488270
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
    Plosker GL.
    Drugs; 2011 Jan 01; 71(1):101-8. PubMed ID: 21175243
    [Abstract] [Full Text] [Related]

  • 7. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB.
    Vaccine; 2012 Jun 19; 30(29):4394-7. PubMed ID: 22122856
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators.
    N Engl J Med; 2010 Jul 29; 363(5):411-22. PubMed ID: 20818862
    [Abstract] [Full Text] [Related]

  • 10. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis.
    Kawalec P, Paszulewicz A, Holko P, Pilc A.
    Arch Med Sci; 2012 Nov 09; 8(5):767-75. PubMed ID: 23185184
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current vaccination strategies for prostate cancer.
    Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.
    Eur Urol; 2012 Feb 09; 61(2):290-306. PubMed ID: 22001436
    [Abstract] [Full Text] [Related]

  • 13. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
    McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R.
    Cancer Immunol Res; 2014 Oct 09; 2(10):988-99. PubMed ID: 25189164
    [Abstract] [Full Text] [Related]

  • 14. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
    Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB.
    J Urol; 2011 Sep 09; 186(3):877-81. PubMed ID: 21788048
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006 Sep 09; 7(3):197-201. PubMed ID: 16752945
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL.
    J Natl Cancer Inst; 2020 Jun 01; 112(6):562-573. PubMed ID: 32145020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.